The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02984475|
Recruitment Status : Unknown
Verified July 2018 by Mona Sobhy Abd El-Mon'em Gaber, Cairo University.
Recruitment status was: Recruiting
First Posted : December 7, 2016
Last Update Posted : July 18, 2018
Beta Thalassemia is a major public health problem in Mediterranean countries.In Egypt, it is considered as the most common chronic hemolytic anemia.one of the major complications in this inherited disorder is iron overload which lead to oxidative stress and tissue damage.
Regarding toxic effect of iron overload on liver, hepatomegaly is one of the most findings that resulting from hemosiderosis, extra medullary hematopoiesis, transmitted hepatitis B and C and cirrhosis.
A lot of studies have been carried out recently to study the beneficial role of metformin in non-diabetic patients of different disorders as non-alcoholic fatty liver disease (NAFLD).Among several studies, it's demonstrated that metformin significantly improved insulin resistance, aminotransferase levels and liver morphology.
The role of metformin in these studies is mainly thought to be antioxidant and anti-inflammatory effects. However, the role of Metformin on hepatic function in different populations with the same mechanism of liver injury should be further investigated.
This clinical trial will be carried out on 60 patients with beta thalassemia major receiving regular blood transfusion and iron chelating therapy, either HCV positive or negative patients.
They will be randomly distributed into either control group (group 1, n=30) receiving blood transfusion and taking iron chelating therapy or treatment group (group 2, n=30) receiving blood transfusion and taking iron chelating therapy along with metformin tablets (500 mg/twice daily) for 6 months.
|Condition or disease||Intervention/treatment||Phase|
|Beta Thalassemia Major Anemia||Drug: Metformin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major|
|Study Start Date :||December 2016|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||April 2019|
Active Comparator: treatment arm
30 patients receiving blood transfusion and taking iron-chelating therapy along with metformin tablets (500 mg once daily for the first week then twice daily for 6 months).
Other Name: Cidophage
No Intervention: control arm
30 patients receiving blood transfusion and taking iron-chelating therapy.
- liver enzymes tests. [ Time Frame: 6 months ]Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST).
- Metformin Safety - Number of participants with treatment-related adverse events [ Time Frame: 6 months ]Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- liver enzymes and function tests - Alkaline phosphatase (ALP). [ Time Frame: 6 months. ]Alkaline phosphatase (ALP).
- liver enzymes and function tests - Gama-Glutamyl transferase (GGT). [ Time Frame: 6 months. ]Gama-Glutamyl transferase (GGT).
- liver enzymes and function tests - total and direct bilirubin. [ Time Frame: 6 months. ]total and direct bilirubin.
- liver enzymes and function tests - Albumin. [ Time Frame: 6 months. ]Albumin .
- liver enzymes and function tests - International Normalized Ratio (INR). [ Time Frame: 6 months. ]International Normalized Ratio (INR).
- oxidative stress markers (MDA). [ Time Frame: 6 months. ]Malondialdehyde (MDA)
- oxidative stress markers (TAC). [ Time Frame: 6 months. ]Total antioxidant capacity (TAC).
- Fibroscan. [ Time Frame: 6 months ]Fibroscan will be done for each patient before and at the end of the study.
- FIB 4 score. [ Time Frame: 6 months ]Fibrosis 4 score.
- APRI score. [ Time Frame: 6 months ]AST to platelet ratio index score.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02984475
|Abo El Reesh Hospital||Recruiting|
|Contact: Mona Gaber, Bachelor. 0223648368 firstname.lastname@example.org|
|El Demerdash (Ain Shams Teaching Hospital).||Completed|